No Data
Jiangsu Apon Medical Technology (300753.SZ): has not yet expanded into the Russian-Ukrainian market and the Middle Eastern market, and currently has no overseas business revenue.
On March 31, Gelonghui reported that Jiangsu Apon Medical Technology (300753.SZ) stated on the investor interaction platform that the company's products are currently mainly developed in the domestic market and have not yet expanded into the Russia-Ukraine and Middle East markets. There are currently no overseas business revenues. The company is also actively trying to explore overseas market demand, analyzing the development space for the company's products in overseas markets, and seeking opportunities for overseas business development.
Jiangsu Apon Medical Technology Co., Ltd.'s (SZSE:300753) 45% Share Price Surge Not Quite Adding Up
Retail Investors Invested in Jiangsu Apon Medical Technology Co., Ltd. (SZSE:300753) up 19% Last Week, Insiders Too Were Rewarded
Jiangsu Apon Medical Technology (SZSE:300753) Hikes 25% This Week, Taking One-year Gains to 142%
Jiangsu Apon Medical Technology Co., Ltd.'s (SZSE:300753) Shares Climb 43% But Its Business Is Yet to Catch Up
Jiangsu apon medical technology (300753.SZ): The anesthesia siasun robot&automation project is still in the design and development stage, without obtaining registration certification and not yet in production.
On December 6, Gelonghui reported that jiangsu apon medical technology (300753.SZ) stated on the investor interaction platform that the company's anesthesia robot project is still in the design and development stage, has not obtained registration certification and has not achieved production. This project has high technical requirements, and currently has met the preset parameter requirements in simulation tissues, with good accuracy and repeatability, and is further optimizing its performance in animal tissues. The project is progressing normally according to the company's project plan.
Jiangsu Apon Medical Technology Co., Ltd. (SZSE:300753) Not Doing Enough For Some Investors As Its Shares Slump 25%